Warner Chilcott Announces FDA Approval of New Ulcerative Colitis Product

Warner Chilcott Announces FDA Approval of New Ulcerative Colitis Product

DUBLIN, Ireland, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Warner Chilcott plc
(Nasdaq:WCRX) today announced that the United States Food and Drug
Administration (FDA) has approved its new 400 mg mesalamine product indicated
for the treatment of ulcerative colitis. The product will be marketed as
DELZICOL™ (mesalamine) 400 mg delayed-release capsules. The Company
anticipates that it will commercially launch DELZICOL in March 2013.


DELZICOL (mesalamine) delayed-release capsules are indicated for the treatment
of mildly to moderately active ulcerative colitis and for the maintenance of
remission of ulcerative colitis. For information on dosage and administration,
contraindications, warnings and precautions, adverse reactions, and other
important safety and other prescribing information see

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently
focused on the women's healthcare, gastroenterology, urology and dermatology
segments of the branded pharmaceuticals market, primarily in North America. We
are a fully integrated company with internal resources dedicated to the
development, manufacture and promotion of our products.


Forward Looking Statements

This press release contains forward-looking statements, including statements
concerning our industry, our operations, our anticipated financial performance
and financial condition and our business plans, growth strategy and product
development efforts. These statements constitute forward-looking statements
within the meaning of Section27A of the Securities Act of 1933 and
Section21E of the Securities Exchange Act of 1934. The words "may," "might,"
"will," "should," "estimate," "project," "plan," "anticipate," "expect,"
"intend," "outlook," "believe" and other similar expressions are intended to
identify forward-looking statements. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of their
dates. These forward-looking statements are based on estimates and assumptions
by our management that, although we believe to be reasonable, are inherently
uncertain and subject to a number of risks and uncertainties. The following
represent some, but not necessarily all, of the factors that could cause
actual results to differ from historical results or those anticipated or
predicted by our forward-looking statements: our substantial indebtedness,
including increases in the LIBOR rates on our variable-rate indebtedness above
the applicable floor amounts; competitive factors and market conditions in the
industry in which we operate, including the approval and introduction of
generic or branded products that compete with our products; our ability to
protect our intellectual property; a delay in qualifying any of our
manufacturing facilities that produce our products, production or regulatory
problems with either our own manufacturing facilities or those of third party
manufacturers, packagers or API suppliers upon whom we may rely for some of
our products or other disruptions within our supply chain; pricing pressures
from reimbursement policies of private managed care organizations and other
third party payors, government sponsored health systems and regulatory
reforms, and the continued consolidation of the distribution network through
which we sell our products; changes in tax laws or interpretations that could
increase our consolidated tax liabilities; government regulation, including
U.S. and foreign health care reform, affecting the development, manufacture,
marketing and sale of pharmaceutical products, including our ability and the
ability of companies with whom we do business to obtain necessary regulatory
approvals; adverse outcomes in our outstanding litigation, regulatory or
arbitration matters or an increase in the number of such matters to which we
are subject; the loss of key senior management or scientific staff; our
ability to manage the growth of our business by successfully identifying,
developing, acquiring or licensing new products at favorable prices and
marketing such new products; our ability to obtain regulatory approval and
customer acceptance of new products, and continued customer acceptance of our
existing products; and the other risks identified in our periodic filings
including our Annual Report on Form 10-K for the year ended December31, 2011,
and from time-to-time in our other investor communications.

We caution you that the foregoing list of important factors is not exclusive.
In addition, in light of these risks and uncertainties, the matters referred
to in our forward-looking statements may not occur. We undertake no obligation
to publicly update or revise any forward-looking statement as a result of new
information, future events or otherwise, except as may be required by law.

CONTACT: Rochelle Fuhrmann
         Investor Relations

Warner Chilcott Logo
Press spacebar to pause and continue. Press esc to stop.